Beigene has quickly become a force in cancer drug development, earning approvals in the U.S. and China for its targeted therapy Brukinsa and immunotherapy tislelizumab. The biotech is developing a slate of small molecule and antibody drugs aimed at several well-known targets, too.
In late 2019, Amgen agreed to pay nearly $3 billion for a 20% stake in Beigene. Notably, Beigene agreed to help Amgen develop as many as 20 experimental drugs and chip in funding as well, a sign of Amgen’s confidence in the company’s research skills.
So far, all of the drugs Beigene has advanced into clinical testing have been small molecules or antibodies. The Shoreline deal will expand the company’s work to include cell therapy, an area that’s growing quickly to encompass multiple types of treatment and technologies. READ MORE
By Ned Pagliarulo
Source: biopharmadive.com
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.
